Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Marc Van den Evnde, Benoist Chibaudel et al.|The Lancet Oncology|2023Cited by 244